Analysis for WAT

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $708.5M in 2024-Q2 to about $1.267B in 2026-Q1, a ~79% increase, with a mid-period dip in 2025-Q1 before resuming growth into 2025-Q4. Net Income progressed from about $161.5M in 2024-Q2 to a peak around $225.2M in late 2025, then turned negative in 2026-Q1 (about -$72M), signaling robust top-line momentum but near-term profitability risk.

💰 Margins & Cash Flow

Gross margin remained healthy, roughly 58-61% across most quarters. Operating leverage was generally favorable until 2026-Q1, when operating income turned negative despite higher revenue. Operating cash flow was generally positive (examples: 204.6M, 240.1M, 259.6M, 164.6M across periods). Net cash flow fluctuated as investing and financing activities varied, ending 2026-Q1 softer.

🛡️ Balance Sheet & Liquidity

Assets run around $4.4–4.9B with cash peaking near $588M by 2025-Q3. Long-term debt sits around $1.41–1.76B, with equity near $2.33B, indicating solid liquidity and moderate leverage. Current ratios trend strengthen resilience.

⚠️ Key Drivers & Risks

• Drivers: Strong demand for lab analytics instruments; sustained margins support earnings power.
• Risks: 2026-Q1 profitability erosion and sensitivity to cost mix/CapEx cycles; valuation risk if growth decelerates.